Fundraising Fox

Newpath Partners

Actively deploying

Boston

Fox Verdict
Sign up to see your fit

Fund manager profile

Newpath Partners is a venture fund manager based in Boston. SEC filings show 2 venture funds on record, most recently Newpath Partners IV, L.P. ($300M offering) filed May 2026.

Source: SEC EDGAR Form D filings. Firm website data not yet available.

HQ
Boston, US
Tracked investments
5

What they invest in

from 5 of 5 portfolio companies

Biotech ×5Medical Devices ×5AI & Machine Learning ×2Deep Tech ×2Healthtech ×2

Investments · 5 tracked

founders shown can be your intro path
Exo Therapeuticsexo-therapeutics.comin𝕏✓ verified

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian

Magnet Biomedicinemagnetbio.com✓ verified

Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders. The platform systematically identifies molecular glues capable of targeting historically difficult-to-drug proteins in precision medicine.

AI & Machine LearningBiotechMedical Devices

Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)

nChroma Bionchromabio.com✓ verified

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhD

Myeloid Therapeuticsmyeloidtx.comin𝕏

CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis. The company's multi-immune platform enables off-the-shelf therapies with repeat dosing capability.

AI & Machine LearningBiotechHealthtechMedical Devices

Orbital Therapeuticsorbitaltx.com

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

BiotechHealthtechMedical Devices

Frequently asked questions

Where is Newpath Partners located?
Newpath Partners is headquartered in Boston, US.

Featured in lists